Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Itaru Endo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5520-8114; OpenAlex author ID A5043460153. Sources: OpenAlex.

Their work

Papers
70 (first author 2, last author 34)
Trials
0
Grants
0
Labs led
1
Collaborators
203
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 9 papers · 2015: 3 papers · 2016: none · 2017: 5 papers · 2018: 3 papers · 2019: 8 papers · 2020: 7 papers · 2021: 4 papers · 2022: 3 papers · 2023: 5 papers · 2024: 2 papers · 2025: 12 papers · 2026: 5 papers

Papers 50 of 70

  1. Enhancing the Diagnostic Performance of Repeated Endoscopic Ultrasound-Guided Tissue Acquisition Combined with Surrogate Repeated Endoscopic Retrograde Pancrea… Co-author DOI 10.1007/s10620-025-09373-5↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model. Co-author DOI 10.1111/cas.70246↗
  4. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18555-4↗
  5. High CDCP1 Expression Reflects Immune and Stromal Remodeling and Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.14740/wjon2682↗
  6. Novel machine-learning model for predicting lymph node metastasis in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12836↗
  7. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Last author DOI 10.1002/jhbp.12074↗
  8. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Last author DOI 10.1002/jhbp.12181↗
  9. Methionine restriction inhibits pancreatic cancer proliferation while suppressing JAK2/STAT3 pathway. Last author DOI 10.1016/j.pan.2024.11.023↗
  10. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). Last author DOI 10.1038/s41598-025-23608-5↗
  11. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  12. Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-17400-y↗
  13. ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transectio… Last author DOI 10.1245/s10434-025-17508-1↗
  14. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17988-1↗
  15. ASO Author Reflections: Comparison Between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-025-18116-9↗
  16. Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Ge… Last author DOI 10.14740/wjon2563↗
  17. Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer. Last author DOI 10.21873/anticanres.17554↗
  18. SLC7A11 and the glutathione pathway as novel prognostic markers in resectable pancreatic ductal adenocarcinoma: A metabolomics study of clinical specimens. Last author DOI 10.1016/j.pan.2024.05.530↗
  19. Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer. Co-author DOI 10.3390/tomography10100117↗
  20. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Last author DOI 10.1002/jhbp.1245↗
  21. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  22. A Case of BRCA2-Pathogenic Variant Breast Cancer With Metachronous Endometrial Cancer and Pancreatic Cancer. Last author DOI 10.14740/wjon1658↗
  23. Pancreatic ductal adenocarcinoma with a high expression of alcohol dehydrogenase 1B is associated with less aggressive features and a favorable prognosis. Co-author PMID 37693153↗
  24. High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis. Co-author PMID 37818071↗
  25. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Last author DOI 10.1002/jhbp.1049↗
  26. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. First author DOI 10.1002/jhbp.1127↗
  27. CRMP4 Up-regulates M2 Macrophages and Myeloid-derived Suppressor Cells to Promote Pancreatic Cancer in Mice. Last author DOI 10.21873/anticanres.15537↗
  28. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemorad… Last author DOI 10.1002/jhbp.883↗
  29. Covered metallic stent placement for biliary drainage could be promising in the coming era of neoadjuvant chemo-radiation therapy for all pancreatic cancer. Co-author DOI 10.1002/jhbp.958↗
  30. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer. Co-author DOI 10.3390/cells10030653↗
  31. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. Co-author PMID 34249445↗
  32. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. Last author DOI 10.1007/s00268-020-05503-4↗
  33. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  34. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… Co-author DOI 10.1016/j.canlet.2020.07.034↗
  35. Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer. Last author DOI 10.1016/j.tranon.2020.100746↗
  36. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  37. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Co-author DOI 10.3390/cancers12102871↗
  38. A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers12123635↗
  39. Role of the tumor microenvironment in pancreatic cancer. Last author DOI 10.1002/ags3.12225↗
  40. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Fo… Last author DOI 10.1007/s00268-019-05159-9↗
  41. Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial (UMIN0000… Last author DOI 10.1016/j.clnesp.2019.07.017↗
  42. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.pan.2018.11.001↗
  43. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  44. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  45. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negativ… Last author DOI 10.1245/s10434-019-07793-y↗
  46. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative R… Last author DOI 10.21873/anticanres.13615↗
  47. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  48. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. Last author DOI 10.1016/j.jss.2017.11.009↗
  49. [III. Resection Margins and R1 Resection in Pancreatic Cancer]. Last author PMID 30382038↗
  50. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Last author DOI 10.1002/jso.24681↗

Closest collaborators

The 25 strongest of 203 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kentaro Miyake · 17 shared papers, 2017–2026 · strength 3.05
  2. Yuki Homma · 20 shared papers, 2014–2026 · strength 2.76
  3. Yasuhiro Yabushita · 16 shared papers, 2017–2026 · strength 2.73
  4. Masanori Oshi · 11 shared papers, 2020–2026 · strength 2.15
  5. Yukihiko Hiroshima · 22 shared papers, 2013–2026 · strength 1.84
  6. Takashi Murakami · 19 shared papers, 2014–2026 · strength 1.83
  7. Sohei Satoi · 9 shared papers, 2019–2026 · strength 1.41
  8. Yasushi Ichikawa · 16 shared papers, 2013–2025 · strength 1.29
  9. Noritoshi Kobayashi · 10 shared papers, 2011–2026 · strength 1.24
  10. Satoshi Hirano · 6 shared papers, 2022–2026 · strength 1.06
  11. Kazuaki Takabe · 6 shared papers, 2020–2023 · strength 1.01
  12. Kensuke Kubota · 8 shared papers, 2011–2026 · strength 1.00
  13. Michiaki Unno · 6 shared papers, 2019–2026 · strength 0.99
  14. Hiroki Yamaue · 7 shared papers, 2019–2026 · strength 0.98
  15. Robert M. Hoffman · 16 shared papers, 2013–2020 · strength 0.92
  16. Masayuki Ohtsuka · 5 shared papers, 2023–2026 · strength 0.89
  17. Michael Bouvet · 15 shared papers, 2013–2020 · strength 0.80
  18. Goro Honda · 4 shared papers, 2025–2026 · strength 0.79
  19. Jun Yamamoto · 3 shared papers, 2020–2026 · strength 0.66
  20. Yusuke Kurita · 4 shared papers, 2019–2026 · strength 0.66
  21. Shuji Isaji · 4 shared papers, 2019–2026 · strength 0.63
  22. Masayuki Sho · 4 shared papers, 2019–2026 · strength 0.63
  23. Kenichi Hakamada · 4 shared papers, 2019–2025 · strength 0.58
  24. Matthew H. G. Katz · 6 shared papers, 2014–2026 · strength 0.57
  25. Sho Hasegawa · 3 shared papers, 2021–2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.